Berkeley, CA – According to filings with the U.S. Securities and Exchange Commission, Xalud Therapeutics is raising $25,150,000.00 in new funding. Sources indicate as part of senior management Executive Chairman, Stephen Collins played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Xalud Therapeutics

Xalud Therapeutics, Inc. is developing novel therapies for the treatment of neuro-inflammatory diseases. Xalud is also developing treatments for inflammatory joint disorders including osteoarthritis and rheumatoid arthritis.

To learn more about Xalud Therapeutics, visit http://www.xaludthera.com/

Contact:
Stephen Collins, Executive Chairman
434-980-8105
https://www.linkedin.com/in/stephen-collins-12604b11/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved